Innomed Ventures

Portfolio · 3

Premia Spine

Spinal Arthroplasty Solutions for Motion Rehabilitation

1 round $15.4M committed Latest: 2014-11

Chiasma

Oral Therapeutic Options for Patients with Rare Diseases

1 round $2.0M committed Latest: 2003-03

Notal Vision

Remote Patient Monitoring for Retinal Diseases

1 round $4.0M committed Latest: 2003-01

Investment activity

1 portfolio exit on record.

Q&A

What is Innomed Ventures' primary investment focus?

Innomed Ventures primarily focuses on the Health Tech & Life Sciences sector, with all three of its portfolio companies and its single exit falling within this area.

Can you name some of Innomed Ventures' notable portfolio companies?

Innomed Ventures' portfolio includes Chiasma, which develops oral therapeutic options for rare diseases, and Notal Vision, focused on remote patient monitoring for retinal diseases.

Has Innomed Ventures had any exits?

Yes, Innomed Ventures had an exit in July 2015 when Chiasma went public on NASDAQ with a valuation of $562M, having raised $102M in capital.

What is the typical investment stage for Innomed Ventures?

Innomed Ventures has participated in Seed, A Round, and B Round funding stages, with one investment in each stage.

When did Innomed Ventures make its most recent recorded investment?

Innomed Ventures made its most recent recorded investment in November 2014.

What kind of solutions does Premia Spine, a portfolio company of Innomed Ventures, offer?

Premia Spine, a portfolio company of Innomed Ventures, provides spinal arthroplasty solutions for motion rehabilitation.